IP Library Granted Patent US 9,040,705
Granted Patent B2
US 9,040,705 · App. 12/757,098 · Granted May 26, 2015

Preparation of saturated ketone morphinan compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,705
App. No.
12/757,098
Granted
May 26, 2015
Kind
B2
Abstract

The present invention provides processes for the preparation of saturated ketone morphinan compounds. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an inorganic salt of a late transition metal.

Claims (43)

1. A one-pot process for the preparation of a morphinan comprising a saturated ketone ring moiety, the process comprising contacting a morphinan comprising an allyl alcohol ring moiety with an inorganic salt of a late transition metal in the presence of a protic solvent, wherein the allyl alcohol ring moiety is catalytically isomerized to the saturated ketone ring moiety, and wherein the weight:weight ratio of the protic solvent to the morphinan comprising an allyl alcohol ring moiety is from 2:1 to 4:1.

2. The process of claim 1 , wherein the late transition metal is a group VIIIB metal selected from the group consisting of ruthenium, rhodium, palladium, osmium, iridium, and platinum; and the inorganic salt is selected from the group consisting of halide, sulfate, phosphate, and nitrate.

3. The process of claim 1 , wherein the inorganic salt of the late transition metal is selected from the group consisting of RuCl 3 , RuBr 3 , Ru(CF 3 SO 3 ) 2 , Ru 2 (SO 4 ) 3 , Ru(NO 3 ) 3 , RhCl 3 , RhBr 3 , Rh 2 (SO 4 ) 3 , [Rh(CO 2 )Cl] 2 , IrCl 3 , OsCl 3 , and PdCl 2 .

4. The process of claim 1 , wherein the weight:weight ratio of the protic solvent to the morphinan comprising an allyl alcohol ring moiety is from 2:1 to 3.6.

5. The process of claim 1 , wherein the process comprises a single inorganic salt of a late transition metal.

6. The process of claim 1 , wherein the morphinan comprising a saturated ketone ring moiety is produced with a yield in excess of 85%.

7. The process of claim 1 , wherein the morphinan comprising a saturated ketone ring moiety is produced with a yield in excess of 95%.

8. A process for the preparation of a compound of Formula (III), the process comprising contacting a compound of Formula (II) with an inorganic salt of a late transition metal in the presence of a protic solvent to form the compound of Formula (III):

wherein:

A is a heteroatom selected from the group consisting of oxygen and sulfur;

R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, protected hydroxy, {—}SH, {—}SR 1611 , {—}OR 1611 , and {—}NR 1611 R 1612 hydrocarbyl, and substituted hydrocarbyl;

R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 14 , R 15a R 15b , R 16a , R 16b , and R 17 are independently selected from the group consisting of hydrogen, halogen, hydroxy, {—}SH, {-}SR 1611 , {—}OR 1611 , and {—}NR 1611 R 1612 , hydrocarbyl, and substituted hydrocarbyl; provided that any of R 10a and R 10b , R 15a and R 15b , and R 16a and R 16b may together form a moiety selected from the group consisting of {═}O, {═}S, and {═}NR 1613 ;

R 1611 , R 1612 , and R 1613 are independently selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl;

one or more of R 1 , R 2 , R 3 , R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 14 , R 15a , R 15b , R 16a , and R 16b may form part of a ring or ring system chosen from carbocyclic, heterocyclic, aryl, heteroaryl, and combinations thereof; and

Z is an anion, and

wherein the weight:weight ratio of the protic solvent to the compound of Formula (II) is from 2:1 to 4:1.

9. The process of claim 8 , wherein A is oxygen; R 1 , R 2 , R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 15a , R 15b , R 16a , and R 16b are hydrogen; R 3 is selected from the group consisting of hydroxy, protected hydroxy, alkyloxy, and acyloxy; R 14 is hydrogen or hydroxy; and R 17 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkylmethyl, allyl, and aryl.

10. The process of claim 9 , wherein R 3 is hydroxy or methyoxy; R 14 is hydrogen; R 17 is methyl; and Z is selected from the group consisting of hydrochloride, sulfate, and bitartrate.

11. The process of claim 8 , wherein the compound of Formula (III) is isolated as a free base of Formula (IV):

wherein:

A is a heteroatom selected from the group consisting of oxygen and sulfur;

R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, protected hydroxy, {—}SH, {—}SR 1611 , {—}OR 1611 , and {—}NR 1611 R 1612 , hydrocarbyl, and substituted hydrocarbyl;

R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 14 , R 15a R 15b , R 16a , R 16b , and R 17 are independently selected from the group consisting of hydrogen, halogen, hydroxy, {—}SH, {—}SR 1611 , {—}OR 1611 , and {—}NR 1611 R 1612 , hydrocarbyl, and substituted hydrocarbyl; provided that any of R 10a and R 10b , R 15a and R 15b , and R 16a and R 16b may together form a moiety selected from the group consisting of {═}O, {═}S, and {—}NR 1613 ;

R 1611 , R 1612 , and R 1613 are independently selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl; and

one or more of R 1 , R 2 , R 3 , R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 14 , R 15a , R 15a , R 16a , and R 16b may form part of a ring or ring system selected from the group consisting of carbocyclic, heterocyclic, aryl, heteroaryl, and combinations thereof.

12. The process of claim 8 , wherein the compound of Formula (II) is formed in situ by contacting an acid with a compound of Formula (I):

wherein:

A is a heteroatom selected from the group consisting of oxygen and sulfur;

R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, protected hydroxy, {—}SH, {—}SR 1611 , {—}OR 1611 and {—}NR 1611 , R 1612 , hydrocarbyl, and substituted hydrocarbyl;

R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 14 , R 15a , R 15b , R 16a , R 16b , and R 17 are independently selected from the group consisting of hydrogen, halogen, hydroxy, {—}SH, {—}SR 1611 , {—}OR 1611 , and {—}NR 1611 R 1612 , hydrocarbyl, and substituted hydrocarbyl; provided that any of R 10a and R 10b , R 15a and R 15b , and R 16a and R 16b may together form a moiety selected from the group consisting of {═}O, {═}S, and {═}NR 1613;

R 1611 , R 1612 , and R 1613 are independently selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl; and

one or more of R 1 , R b 2 ,R 3 , R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 14 , R 15a , R 15b , R 16a , and R 16b may form part of a ring or ring system selected from the group consisting of carbocyclic, heterocyclic, aryl, heteroaryl, and combinations thereof.

13. The process of claim 12 , wherein the acid is selected from the group consisting of sulfuric acid, hydrochloric acid, and tartaric acid.

14. The process of claim 8 , wherein the late transition metal is a group VIIIB metal selected from the group consisting of ruthenium, rhodium, palladium, osmium, iridium, and platinum; and the inorganic salt is selected from the group consisting of halide, sulfate, phosphate, and nitrate.

15. The process of claim 8 , wherein the inorganic salt of the late transition metal is selected from the group consisting of RuCl 3 , RuBr 3 , Ru(CF 3 SO 3 ) 2 , Ru 2 (SO 4 ) 3 , Ru(NO 3 ) 3 , RhCl 3 , RhBr 3 , Rh 2 (SO 4 ) 3 , [Rh(CO 2 )Cl] 2 , IrCl 3 , OsCl 3 , and PdCl 2 .

16. The process of claim 8 , wherein the weight:weight ratio of the compound of Formula (II) to the late transition metal salt is from about 1:0.0001 to about 1:0.1; the protic solvent is selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, isobutanol, n-butanol, s-butanol, t-butanol, formic acid, acetic acid, water, and combinations thereof; and the reaction is conducted at a temperature from about 10° C. to about 120° C.

17. The process of claim 16 , wherein the protic solvent comprises a mixture of alcohol and water.

18. The process of claim 8 , further comprising a co-reactant selected from the group consisting of acetone, acetonitrile, 1-hexene, cyclohexene, H 3 PO 2 , NaH 2 PO 2 , and combinations thereof.

19. The process of claim 8 , wherein the optical activity of the compounds of Formulas (II) and (III) is (−) or (+), and the configuration of C-5, C-13, C-14, and C-9, respectively, is selected from the group consisting of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, and SSSS, provided that the C-15 and the C-16 carbons are both either on the alpha face of the molecule or the beta face of the molecule.

20. The process of claim 10 , wherein the late transition metal salt is RuCl 3 ; the weight:weight ratio of the compound of Formula (II) to RuCl 3 is from about 1:0.01 to about 1:0.2; the protic solvent comprises ethanol and water; the reaction is conducted at a temperature from about 65° C. to about 90° C.; and the compound of Formula (III) has a yield of at least about 60%.

21. The process of claim 17 , further comprising a co-reactant selected from the group consisting of acetone, acetonitrile, 1-hexene, cyclohexene, H 3 PO 2 , NaH 2 PO 2 , and combinations thereof; and the weight:weight ratio of the compound of Formula (II) to the co-reactant is from about 1:0.005 to about 1:0.05.

22. The process of claim 20 , wherein the optical activity of the compounds of Formulas (II) and (III) is (−), and the configuration of C-5, C-13, C-14, and C-9, respectively, is RSRR.

23. The process of claim 20 , wherein the optical activity of the compounds of Formulas (II) and (III) is (+), and the configuration of C-5, C-13, C-14, and C-9, respectively, is SRSS.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2010
From: WANG, PETER X.; JIANG, TAO; BERBERICH, DAVID W.; GURUSAMY, NARAYANASAMY; JUNG, CATHERINE K.
To: MALLINCKRODT INC.
Reel/Frame 024210/0233 →